Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, will be represented at the 2023 Milken Institute Future of Health Summit. According to the announcement, Cybin CEO Doug Drysdale is slated to participate on a panel about innovations in mental health care; … Continue reading InvestorNewsBreaks – Cybin Inc.’s (NEO: CYBN) (NYSE American: CYBN) Announces Participation at Upcoming Milken Institute Future of Health Summit